Cartesian Therapeutics (RNAC) Debt to Equity: 2015-2023
Historic Debt to Equity for Cartesian Therapeutics (RNAC) over the last 8 years, with Dec 2023 value amounting to -$0.06.
- Cartesian Therapeutics' Debt to Equity fell 122.98% to -$0.06 in Q4 2023 from the same period last year, while for Dec 2023 it was -$0.06, marking a year-over-year decrease of 122.98%. This contributed to the annual value of -$0.06 for FY2023, which is 122.98% down from last year.
- Per Cartesian Therapeutics' latest filing, its Debt to Equity stood at -$0.06 for Q4 2023, which was down 117.52% from $0.37 recorded in Q2 2023.
- In the past 5 years, Cartesian Therapeutics' Debt to Equity registered a high of $384.79 during Q2 2019, and its lowest value of -$5.97 during Q2 2021.
- Over the past 3 years, Cartesian Therapeutics' median Debt to Equity value was $0.29 (recorded in 2022), while the average stood at -$0.50.
- Its Debt to Equity has fluctuated over the past 5 years, first skyrocketed by 43,911.27% in 2019, then tumbled by 425.67% in 2021.
- Cartesian Therapeutics' Debt to Equity (Quarterly) stood at $2.25 in 2019, then crashed by 161.16% to -$1.38 in 2020, then spiked by 182.66% to $1.14 in 2021, then tumbled by 75.41% to $0.28 in 2022, then plummeted by 122.98% to -$0.06 in 2023.
- Its Debt to Equity stands at -$0.06 for Q4 2023, versus $0.37 for Q2 2023 and $0.35 for Q1 2023.